Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Space Flight | 11 | 2009 | 117 | 0.920 |
Why?
|
| Weightlessness | 7 | 2008 | 46 | 0.820 |
Why?
|
| Astronauts | 6 | 2009 | 51 | 0.760 |
Why?
|
| Aerospace Medicine | 6 | 2008 | 37 | 0.640 |
Why?
|
| Radiation-Protective Agents | 3 | 2011 | 18 | 0.440 |
Why?
|
| Extraterrestrial Environment | 3 | 2007 | 6 | 0.360 |
Why?
|
| Medullary Sponge Kidney | 1 | 2008 | 2 | 0.310 |
Why?
|
| Radiation, Ionizing | 2 | 2007 | 41 | 0.290 |
Why?
|
| Linear Energy Transfer | 2 | 2007 | 7 | 0.290 |
Why?
|
| Immunotherapy, Active | 1 | 2007 | 18 | 0.280 |
Why?
|
| Gamma Rays | 1 | 2007 | 49 | 0.280 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2007 | 22 | 0.280 |
Why?
|
| Urinary Catheterization | 1 | 2007 | 81 | 0.270 |
Why?
|
| Urogenital System | 1 | 2005 | 34 | 0.250 |
Why?
|
| Military Personnel | 1 | 2008 | 212 | 0.250 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 192 | 0.240 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 381 | 0.240 |
Why?
|
| Urinary Calculi | 2 | 2008 | 18 | 0.240 |
Why?
|
| Reproduction | 1 | 2005 | 238 | 0.210 |
Why?
|
| Gravitation | 2 | 2000 | 12 | 0.200 |
Why?
|
| Epithelial Cells | 1 | 2007 | 909 | 0.200 |
Why?
|
| Aircraft | 1 | 2000 | 19 | 0.170 |
Why?
|
| Neck Pain | 1 | 2000 | 19 | 0.170 |
Why?
|
| Cervical Vertebrae | 1 | 2000 | 114 | 0.160 |
Why?
|
| Ecological Systems, Closed | 2 | 2008 | 2 | 0.150 |
Why?
|
| Space Simulation | 2 | 2007 | 4 | 0.140 |
Why?
|
| Endoscopy | 1 | 1999 | 280 | 0.140 |
Why?
|
| Dogs | 2 | 2007 | 767 | 0.130 |
Why?
|
| Telemedicine | 1 | 1999 | 428 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2006 | 1213 | 0.100 |
Why?
|
| Penile Neoplasms | 1 | 1992 | 33 | 0.100 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 64 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 137 | 0.090 |
Why?
|
| Weightlessness Countermeasures | 2 | 2008 | 4 | 0.080 |
Why?
|
| Rhabdomyosarcoma | 1 | 1992 | 191 | 0.080 |
Why?
|
| Musculoskeletal System | 1 | 2009 | 18 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 335 | 0.080 |
Why?
|
| Life Support Systems | 1 | 2008 | 6 | 0.080 |
Why?
|
| Kidney Medulla | 1 | 2008 | 19 | 0.070 |
Why?
|
| Taxoids | 2 | 2006 | 67 | 0.070 |
Why?
|
| Kidney Calculi | 1 | 2008 | 42 | 0.070 |
Why?
|
| Prednisone | 2 | 2006 | 275 | 0.070 |
Why?
|
| Cystostomy | 1 | 2007 | 3 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 64 | 0.070 |
Why?
|
| Horses | 1 | 2007 | 91 | 0.070 |
Why?
|
| Geography | 1 | 2007 | 112 | 0.070 |
Why?
|
| Antigens | 1 | 2007 | 155 | 0.070 |
Why?
|
| Lipid Peroxidation | 1 | 2007 | 87 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2007 | 970 | 0.070 |
Why?
|
| Chemoprevention | 1 | 2007 | 57 | 0.070 |
Why?
|
| Sheep | 1 | 2007 | 219 | 0.070 |
Why?
|
| Sus scrofa | 1 | 2007 | 125 | 0.070 |
Why?
|
| Animals | 5 | 2011 | 34046 | 0.070 |
Why?
|
| Radiation Dosage | 1 | 2007 | 135 | 0.070 |
Why?
|
| Thoracic Injuries | 1 | 2007 | 91 | 0.070 |
Why?
|
| Immune System | 1 | 2007 | 90 | 0.070 |
Why?
|
| Calcinosis | 1 | 2008 | 177 | 0.070 |
Why?
|
| Abdomen | 1 | 2007 | 127 | 0.070 |
Why?
|
| Cell Death | 1 | 2007 | 238 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 1544 | 0.060 |
Why?
|
| Rabbits | 1 | 2007 | 708 | 0.060 |
Why?
|
| Abdominal Injuries | 1 | 2007 | 109 | 0.060 |
Why?
|
| Cattle | 1 | 2007 | 565 | 0.060 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2006 | 100 | 0.060 |
Why?
|
| Humans | 24 | 2009 | 124240 | 0.060 |
Why?
|
| Urologic Diseases | 1 | 2005 | 44 | 0.060 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2005 | 70 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2008 | 232 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2007 | 381 | 0.060 |
Why?
|
| Estramustine | 1 | 2004 | 4 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2006 | 256 | 0.060 |
Why?
|
| Hemostatic Techniques | 1 | 2005 | 32 | 0.060 |
Why?
|
| Physical Exertion | 1 | 2004 | 79 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2007 | 483 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 616 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 1107 | 0.060 |
Why?
|
| Ultrasonography | 3 | 2007 | 931 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2004 | 49 | 0.050 |
Why?
|
| Swine | 1 | 2007 | 1177 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2007 | 368 | 0.050 |
Why?
|
| Male | 13 | 2009 | 61023 | 0.050 |
Why?
|
| United States | 5 | 2009 | 10868 | 0.050 |
Why?
|
| Motion Sickness | 1 | 2002 | 12 | 0.050 |
Why?
|
| Equipment Design | 2 | 2004 | 587 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2007 | 800 | 0.050 |
Why?
|
| Testicular Neoplasms | 2 | 1995 | 132 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2002 | 87 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2005 | 301 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2005 | 467 | 0.050 |
Why?
|
| Biomarkers | 2 | 2007 | 3049 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 2001 | 75 | 0.050 |
Why?
|
| Rats | 1 | 2007 | 3676 | 0.040 |
Why?
|
| Lens, Crystalline | 1 | 2001 | 137 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1992 | 3549 | 0.040 |
Why?
|
| Weight Lifting | 1 | 2000 | 6 | 0.040 |
Why?
|
| Head Movements | 1 | 2000 | 24 | 0.040 |
Why?
|
| Intervertebral Disc | 1 | 2000 | 12 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2001 | 747 | 0.040 |
Why?
|
| Ergonomics | 1 | 2000 | 19 | 0.040 |
Why?
|
| Spinal Diseases | 1 | 2000 | 45 | 0.040 |
Why?
|
| Exercise | 2 | 2009 | 787 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2000 | 167 | 0.040 |
Why?
|
| Posture | 1 | 2000 | 137 | 0.040 |
Why?
|
| Cataract | 1 | 2001 | 222 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 1476 | 0.040 |
Why?
|
| United States National Aeronautics and Space Administration | 2 | 2008 | 19 | 0.040 |
Why?
|
| Radiation Protection | 2 | 2008 | 54 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 1010 | 0.030 |
Why?
|
| Space Suits | 2 | 2007 | 5 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2001 | 555 | 0.030 |
Why?
|
| Mitoxantrone | 2 | 2006 | 26 | 0.030 |
Why?
|
| Image Cytometry | 1 | 1995 | 13 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 2498 | 0.030 |
Why?
|
| Mice | 2 | 2011 | 17625 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 301 | 0.030 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1993 | 18 | 0.030 |
Why?
|
| Prostatitis | 1 | 1993 | 13 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1993 | 44 | 0.030 |
Why?
|
| Prevalence | 1 | 2000 | 2445 | 0.030 |
Why?
|
| Risk Factors | 3 | 2007 | 10248 | 0.030 |
Why?
|
| Prostatic Hyperplasia | 1 | 1993 | 117 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2006 | 5129 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2006 | 1491 | 0.020 |
Why?
|
| Lethal Dose 50 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Female | 6 | 2011 | 66304 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2000 | 3415 | 0.020 |
Why?
|
| Androgens | 1 | 1993 | 274 | 0.020 |
Why?
|
| Ejaculation | 1 | 1990 | 20 | 0.020 |
Why?
|
| Time Factors | 3 | 2007 | 6283 | 0.020 |
Why?
|
| Prostate | 1 | 1993 | 435 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1990 | 30 | 0.020 |
Why?
|
| Liposomes | 1 | 2011 | 174 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 1993 | 413 | 0.020 |
Why?
|
| Adult | 4 | 2009 | 29359 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 510 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1990 | 87 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 1990 | 163 | 0.020 |
Why?
|
| Back Injuries | 1 | 2009 | 4 | 0.020 |
Why?
|
| Foot Injuries | 1 | 2009 | 7 | 0.020 |
Why?
|
| Health Facility Planning | 1 | 2008 | 3 | 0.020 |
Why?
|
| Time | 1 | 2008 | 93 | 0.020 |
Why?
|
| Extravehicular Activity | 1 | 2007 | 4 | 0.020 |
Why?
|
| Facility Design and Construction | 1 | 2007 | 4 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2006 | 16293 | 0.020 |
Why?
|
| Arctic Regions | 1 | 2007 | 3 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2011 | 476 | 0.020 |
Why?
|
| Aged | 5 | 2006 | 19537 | 0.020 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2007 | 32 | 0.020 |
Why?
|
| Virus Latency | 1 | 2007 | 61 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2007 | 217 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 116 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 212 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2007 | 329 | 0.020 |
Why?
|
| Canada | 1 | 2007 | 300 | 0.020 |
Why?
|
| Internationality | 1 | 2007 | 131 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 196 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 3038 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2007 | 480 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 276 | 0.020 |
Why?
|
| Viral Load | 1 | 2007 | 384 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2007 | 251 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2006 | 272 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 394 | 0.010 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2004 | 7 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2006 | 6464 | 0.010 |
Why?
|
| Nail Diseases | 1 | 2004 | 15 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 471 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 776 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2007 | 676 | 0.010 |
Why?
|
| Diet | 1 | 2011 | 1133 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1989 | 643 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2004 | 116 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 1992 | 1650 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 1085 | 0.010 |
Why?
|
| Middle Aged | 4 | 2006 | 26601 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 1348 | 0.010 |
Why?
|
| Vasomotor System | 1 | 2002 | 25 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 4401 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 1289 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 3135 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 1104 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2002 | 304 | 0.010 |
Why?
|
| Palliative Care | 1 | 2004 | 427 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2001 | 126 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2143 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2001 | 183 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 2861 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 716 | 0.010 |
Why?
|
| Cisplatin | 1 | 2001 | 234 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2001 | 198 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 1708 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1320 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 3431 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 1228 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1989 | 3065 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1992 | 13997 | 0.010 |
Why?
|
| Survival Rate | 1 | 2001 | 2040 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2001 | 662 | 0.010 |
Why?
|
| Quality of Life | 1 | 2004 | 1900 | 0.010 |
Why?
|
| Cell Division | 1 | 1993 | 776 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1995 | 1233 | 0.010 |
Why?
|
| Adrenergic Fibers | 1 | 1990 | 4 | 0.010 |
Why?
|
| Retroperitoneal Space | 1 | 1990 | 19 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 1990 | 63 | 0.010 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1989 | 8 | 0.010 |
Why?
|
| Cyclosporins | 1 | 1989 | 74 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1990 | 411 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1989 | 186 | 0.000 |
Why?
|
| Ureteral Obstruction | 1 | 1989 | 105 | 0.000 |
Why?
|
| Graft Rejection | 1 | 1989 | 589 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2001 | 12289 | 0.000 |
Why?
|
| Signal Transduction | 1 | 1993 | 4504 | 0.000 |
Why?
|